Mangaluru girl Beulah Ruth Pinto is UAE’s Best Young Singer

Bengaluru, Jul 22: Karnataka's Covid-19 task force on Tuesday decided that the state government will regulate the supply of Remdesivir, the drug used in the treatment of coronavirus infected patients, to private hospitals to check black marketing and hoarding.

"Remdesivir which is currently available in the government hospitals will be supplied to private hospitals through the government.

This will help curb black marketing of this drug," Medical Education Minister K Sudhakar's office said in a release.

Along with Sudhakar, other task force members, including Health Minister Sriramulu, Deputy Chief Minister C N Ashwath Narayan and Chief Secretary T M Vijay Bhaskar attended the meeting. However, Home Minister Basavaraj Bommai was not part of it as he was out of Bengaluru.

At the meeting, the government has also fixed the rate for Covid-19 tests in private labs- Rs 2,000 for government referred cases and 3,000 for self-reporting cases.

It was also decided to purchase 4 lakh antigen test kits and 5 lakh swab test kits to ramp up testing, the release said, adding that approvals have also been given for additional drugs for the treatment of Covid-19 patients.

The decisions also included increasing monthly salary for Ayush doctors to 48,000, MBBS doctors to 80,000 and nurses to get 30,000 for next 6 months.

The task force also made it clear that private hospitals have to reserve 50 percent beds for the government for Covid-19 treatment. The remaining 50 percent can be used by the private hospitals for Covid-19 and non-Covid-19 treatment.

Private hospitals provide treatment under Ayushman Bharat scheme (ABARK) for Covid-19 patients.

Those cases in which treatment does not cover under the scheme can be charged as per the user charges, the release said.

A committee will be formed to supervise and recommend the purchase of equipment and medicines for Covid-19 treatment, which will be headed by ACS, ITBT Department.

Approval has been given for the procurement of N-95 masks and lakh PPE kits for the safety of healthcare workers. The decision also has been taken to connect oxygen pipeline to 4,736 beds in 17 government medical colleges, which will enable high flow oxygen for these beds besides being beneficial for future use as well.

According to the release, 16 RTPCR and 15 Automated RNA extraction units will be established to ramp up testing and this will help achieve the target of 50,000 tests per day. "On the whole approvals given for purchase of equipment and upgradation of existing facilities at government hospitals is estimated to be about Rs 500 Crore," it added.

University of Oxford researchers have claimed that a cheap and widely available drug called dexamethasone can help save the lives of patients who are seriously ill with coronavirus.

Scientists working on the Recovery Trial found the drug could help patients on ventilators and oxygen, but had no effect on those who did not need help breathing.

“Based on these results, one death would be prevented by treatment of around eight ventilated patients or around 25 patients requiring oxygen alone,” researchers said in a statement.

Matt Hancock, the health secretary, tweeted: “This global first exemplifies the power of science.”

“I’m absolutely delighted that today we can announce the first successful clinical trial for a treatment for Covid-19,” Mr Hancock said.

Recovery Trial experts said a randomised group of 2,104 patients was given 6mg of dexamethasone per day for 10 days, while another group of 4,321 were given normal treatment.

Dexamethasone reduced deaths by one-fifth in patients on oxygen feeds and by one-third in those who needed a ventilator to breathe, preliminary results showed.

Mr Hancock added: “This is a huge step forward and it’s because we’ve backed the science.”

Martin Landray, professor of medicine and epidemiology at the Nuffield Department of Population Health, University of Oxford, and one of the trial’s chief investigators, said in a statement: “These preliminary results from the Recovery Trial are very clear – dexamethasone reduces the risk of death among patients with severe respiratory complications.

“Covid-19 is a global disease – it is fantastic that the first treatment demonstrated to reduce mortality is one that is instantly available and affordable worldwide.”

Bengaluru, May 27: A 69-year-old woman from Yadgiri became the 45th COVID-19 related fatality in Karnataka, where 122 fresh cases have been reported, taking the total number of infections in the state to 2,405, the health department said on Wednesday.

With 45 deaths and 762 discharges, there are 1,596 active coronavirus cases in the state, the department said in its mid-day bulletin. It said, the deceased woman, a returnee from Maharashtra was brought dead to designated hospital in Yadgiri on May 20 and tested positive for COVID-19.

Fourteen patients have been discharged in the state so far on Wednesday. Of the 122 new cases, 108 are returnees from neighboring Maharashtra, three from Tamil Nadu, and one each from Uttar Pradesh, Gujarat, Madhya Pradesh, Kerala and Delhi. While two are returnees from foreign countries- one each from UAE and Nepal.

Remaining four cases are contact of patients earlier tested positive.

Among the districts where new cases were reported, Kalaburagi accounted for 28, Yadgiri 16, Hassan 15, Bidar 13, Dakshina Kannada 11, Udupi 9, Bengaluru Urban 6, five each from Uttara Kannada and Raichur, Belagavi 4, Chikkamagaluru 3, two each from Bengaluru Rural and Vijayapura, and one each from Ballari, Mandya and Tumakuru.